Page last updated: 2024-11-04

lobenzarit

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lobenzarit: prevents autoimmune kidney disease in hybrid mice; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3946
CHEMBL ID1986706
CHEBI ID135215
SCHEMBL ID187951
MeSH IDM0065233

Synonyms (30)

Synonym
lobenzarit
2-((2-carboxyphenyl)amino)-4-chlorobenzoic acid
4-chlor-2,2'-iminodibenzoesaiure
lobenzaritum [inn-latin]
benzoic acid, 2-((2-carboxyphenyl)amino)-4-chloro-
CHEBI:135215
63329-53-3
111GE011
2-[(2-carboxyphenyl)amino]-4-chlorobenzoic acid
2-(2-carboxyanilino)-4-chlorobenzoic acid
2-[(2-carboxyphenyl)amino]-4-chloranyl-benzoic acid
A834330
CHEMBL1986706
lobenzarit [inn]
915ee91p39 ,
unii-915ee91p39
lobenzaritum
FT-0630737
lobenzarit [mi]
lobenzarit [who-dd]
4-chloro-2,2'-iminodibenzoate
SCHEMBL187951
DTXSID20212709
AS-71902
2-(2-carboxyphenylamino)-4-chlorobenzoic acid
Q6663655
AKOS037647002
HY-124411
bdbm50591384
F75214

Research Excerpts

Overview

Lobenzarit disodium is a drug for the treatment of rheumatoid arthritis. It is a newly developed immunomodulating drug that has been demonstrated to enhance suppressor T-cell number and function.

ExcerptReferenceRelevance
"Lobenzarit disodium is a drug for the treatment of rheumatoid arthritis. "( Evaluation of Eudragit RS-PO and Ethocel 100 matrices for the controlled release of lobenzarit disodium.
Alvarez-Fuentes, J; Boza, A; Caraballo, I; Rabasco, AM, 1999
)
1.97
"Lobenzarit (CCA) is a newly developed immunomodulating drug that has been demonstrated to enhance suppressor T-cell number and function. "( Effects of lobenzarit on murine acute viral myocarditis.
Kanda, T; Murata, K; Suzuki, T; Yokoyama, T, 1992
)
2.12
"Lobenzarit (CCA) is a novel disease modifying anti-rheumatic drug. "( Regulation of in vitro anti-DNA antibody production by a novel disease modifying anti-rheumatic drug, Lobenzarit.
Hirohata, S,
)
1.79

Effects

ExcerptReferenceRelevance
"Lobenzarit disodium has no effect on prostaglandin E2 production as measured by radioimmunoassay although two other diphenylamine derivatives have a potent inhibitory activity."( The effect of diphenylamine derivatives on arachidonic acid metabolism in rat peritoneal macrophages.
Fukui, Y; Hirasawa, N; Ohuchi, K; Ozeki, T; Tsurufuji, S; Watanabe, M, 1987
)
0.99

Actions

ExcerptReferenceRelevance
"Lobenzarit did not inhibit cytochromes P-450 1A1/1A2, 2B1/2B2 and 2E1 which were measured as ethoxyresorufin O-deethylation (EROD) activity in beta-naphthoflavone-induced rat liver microsomes, as pentoxyresorufin de-pentylation (PROD) activity in phenobarbital-induced microsomes and as p-nitrophenol hydroxylation (PNPH) activity in pyrazol-induced microsomes."( Mechanism of protection of lobenzarit against paracetamol-induced toxicity in rat hepatocytes.
Commandeur, JN; Groot, E; Remirez, D; Vermeulen, NP, 1995
)
1.31

Dosage Studied

ExcerptRelevanceReference
" On increasing the dosage of CCA to 320 mg/day because of unsatisfactory symptomatic responses elicited at the initial dose level, the patient became free from an asthmatic attack with a return to normal of his eosinophilic count."( [Successful treatment with lobenzarit disodium in case of Churg-Strauss syndrome].
Akiyama, Y; Dohi, Y; Imai, F; Katagiri, T; Ohno, S; Suzuki, T; Tanaka, M, 1993
)
0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aminobenzoic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein polybromo-1Homo sapiens (human)IC50 (µMol)250.00000.63100.63100.6310AID1857772
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
mitotic cell cycleProtein polybromo-1Homo sapiens (human)
chromatin remodelingProtein polybromo-1Homo sapiens (human)
regulation of transcription by RNA polymerase IIProtein polybromo-1Homo sapiens (human)
negative regulation of cell population proliferationProtein polybromo-1Homo sapiens (human)
regulation of mitotic metaphase/anaphase transitionProtein polybromo-1Homo sapiens (human)
positive regulation of T cell differentiationProtein polybromo-1Homo sapiens (human)
positive regulation of cell differentiationProtein polybromo-1Homo sapiens (human)
positive regulation of myoblast differentiationProtein polybromo-1Homo sapiens (human)
regulation of G0 to G1 transitionProtein polybromo-1Homo sapiens (human)
regulation of G1/S transition of mitotic cell cycleProtein polybromo-1Homo sapiens (human)
positive regulation of double-strand break repairProtein polybromo-1Homo sapiens (human)
regulation of nucleotide-excision repairProtein polybromo-1Homo sapiens (human)
transcription elongation by RNA polymerase IIProtein polybromo-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
DNA bindingProtein polybromo-1Homo sapiens (human)
chromatin bindingProtein polybromo-1Homo sapiens (human)
protein bindingProtein polybromo-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
nuclear chromosomeProtein polybromo-1Homo sapiens (human)
kinetochoreProtein polybromo-1Homo sapiens (human)
chromatinProtein polybromo-1Homo sapiens (human)
nucleusProtein polybromo-1Homo sapiens (human)
nucleoplasmProtein polybromo-1Homo sapiens (human)
nuclear matrixProtein polybromo-1Homo sapiens (human)
RSC-type complexProtein polybromo-1Homo sapiens (human)
SWI/SNF complexProtein polybromo-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1857772Inhibition of biotinylated histone H3K14 (1 to 20 residues) peptide binding to His6-tagged recombinant human PBRM1 BD2 transfected in Escherichia coli BL21 (DE3) incubated for 30 mins by Alphascreen assay2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (41.79)18.7374
1990's30 (44.78)18.2507
2000's6 (8.96)29.6817
2010's2 (2.99)24.3611
2020's1 (1.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.67 (24.57)
Research Supply Index4.36 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (5.48%)5.53%
Reviews6 (8.22%)6.00%
Case Studies5 (6.85%)4.05%
Observational0 (0.00%)0.25%
Other58 (79.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]